Analyst Reco. PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
33.01 ^USD	-1.81%		+29.50%	+19.78%

30/04	North American Morning Briefing : More Earnings -2-	DJ
29/04	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	29/04	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating	01/03	MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating	01/03	MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating	26/01	MT
Inflation is just the icing on the cake	26/01
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	26/01	MT
RBC Raises Price Target on PTC Therapeutics to $27 From $23, Keeps Sector Perform Rating	03/01	MT
Morgan Stanley Downgrades PTC Therapeutics to Underweight From Equalweight, Price Target is $28	19/12	MT
North American Morning Briefing : Rate Decisions, -2-	30/23/30	DJ
Morgan Stanley Adjusts Price Target on PTC Therapeutics to $28 From $31, Maintains Equalweight Rating	27/23/27	MT
Barclays Trims Price Target on PTC Therapeutics to $25 From $26, Maintains Equalweight Rating	27/23/27	MT
Citigroup Downgrades PTC Therapeutics to Sell From Neutral	27/23/27	MT
RBC Cuts Price Target on PTC Therapeutics to $23 From $26, Keeps Sector Perform Rating	27/23/27	MT
Truist Securities Downgrades PTC Therapeutics to Hold From Buy, Price Target is $25	06/23/06	MT
Barclays Lowers Price Target on PTC Therapeutics to $26 From $44, Maintains Equalweight Rating	18/23/18	MT
Goldman Sachs Adjusts Price Target on PTC Therapeutics to $22 From $35, Keeps Sell Rating	18/23/18	MT
RBC Cuts Price Target on PTC Therapeutics to $26 From $49 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	18/23/18	MT
Citigroup Downgrades PTC Therapeutics to Neutral From Buy, Cuts Price Target to $29 From $55	18/23/18	MT
JPMorgan Lowers PTC Therapeutics Price Target to $53 From $70, Maintains Overweight Rating	15/23/15	MT
Morgan Stanley Cuts Price Target on PTC Therapeutics to $31 From $47, Maintains Equalweight Rating	15/23/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Analyst Reco.

Filters